Dr. Risa Wong is a Hematology and Oncology fellow at the University of Washington and Fred Hutchinson Cancer Research Center.  The American Board of Internal Medicine has certified her in internal medicine (physician and surgeon). She completed her first degree at the University of Washington and got a medical degree of Yale University School of Medicine.

Profile LinkedIn 

Professor Guido Cavaletti is a professor of human anatomy at the School of Medicine and Surgery, vice-rector for research and Head of Experimental Neurology unit at the University of Milano-Bicocca. He also works as senior consultant neurologist and head of the outpatient clinic at the Department of Neurology, S. Gerardo University Hospital. He is currently the Chair of the Toxic Neuropathy Consortium of the Peripheral Nerve Society

Profile LinkedIn 

Dr. Mario Lacouture is a board-certified dermatologist at Mermorial Sloan Kettering Cancer Center in New York and director of a clinical program in Oncodermatology, first program in the field founded by himself in 2006. He specializes in advancing cancer care and its effect in dermatologic conditions of patients after cancer treatments, such as chemotherapy, radiotherapy, and immunotherapies.

Profile LinkedIn 

 Dr. Dicker is a professor of the Radiation Oncology, Pharmacology, and experimental therapies at Thomas Jefferson University. He serves as co-chair Translational Science Committee for the NCI cooperative group. His research includes the use of “smart needles” for diagnostic and therapeutic applications and he also works in prostate cancer focuses on the “self-seeding” of prostate cells with metastatic properties back to the site of origin, which contributes to disease progression.

Profile LinkedIn 

Dr. Marilyn HUANG is a experienced research director of Translational Gynecologic Oncology and, researcher at Sylvester Comprehensive Cancer Center and associate professor of The University of Miami. Her research is centered on novel therapeutics and innovative drug combinations for trial programs. She has won multiple industry sponsors to evaluate new treatments in gynecologic malignancies, focused in immunotherapy.

Profile LinkedIn 

Professor Lip, MD is a clinical researcher, Price-Evans chair of Cardiovascular Medicine and director of the Liverpool Centre for Cardiovascular Science, at the University of Liverpool, UK. At Aalborg University in Denmark, he is a well-known Professor and adjunct professor at Yonsei University in Korea.

Professor Dame Lesley Fallowfield is professor of Psycho-oncology at Brighton & Sussex Medical School, University of Sussex where she is director of Sussex Health Outcomes research & education in cancer. Her research interests include assessment of patient reported outcomes (PROs), supportive interventions for symptoms and side-effects of cancer and its treatments. In her career path she has published over 400 papers, book chapters and 3 textbooks. She also lectures and runs training workshops around the world in psychosocial oncology, quality of life assessment and communication skills.

In 2010, she was awarded the Pfizer/BOA Excellence in Oncology Lifetime Achievement Award and in 2016 she was made a Dame Commander of the order of the British Empire after her debut as fellow of the UK Academy of medical Sciences.

Profile LinkedIn 

Professor Karin Jordan is the leading senior physician of the Department of Hematology and Oncology at the University Hospital in Heidelberg, Germany. She also actively works as Chief Physician in the Ernst von Bergmann Clinic in Potsdam. Germany.

Professor Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel in 2009 and 2015 as well as a member of the ASCO antiemetic guideline panel. She is the ESMO Faculty coordinator for Supportive & Palliative Care and the ESMO Clinical Practice Guidelines subject editor for the supportive care section. Professor Jordan has authored and co-authored more than 120 publications. Her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.

Profile LinkedIn

Professor Dame Lesley Fallowfield is professor of Psycho-oncology at Brighton & Sussex Medical School, University of Sussex where she is director of Sussex Health Outcomes research & education in cancer. Her research interests include assessment of patient reported outcomes (PROs), supportive interventions for symptoms and side-effects of cancer and its treatments. In her career path she has published over 400 papers, book chapters and 3 textbooks. She also lectures and runs training workshops around the world in psychosocial oncology, quality of life assessment and communication skills.

In 2010, she was awarded the Pfizer/BOA Excellence in Oncology Lifetime Achievement Award and in 2016 she was made a Dame Commander of the order of the British Empire after her debut as fellow of the UK Academy of medical Sciences.

Profile LinkedIn 

Dr. Matti Aapro is presently Dean of the Multidisciplinary Oncology Institut at Genolier. He is also a Board Member of ECCO (European CanCer Organisation) and he serves the International Society for Geriatric Oncology (SIOG) as Executive Board Member. He is past-President of the Multinational Association for Supportive Care in Cancer (MASCC). He is a member of the ESMO Faculty and chairs the ESMO 2017 Supportive/Palliative Care track. Dr. Aapro is Editor of Critical Reviews in Oncology/Hematology and the Journal of Geriatric Oncology. He has authored more than 350 publications and his major interests are new drug development, breast cancer, cancer in the elderly, and supportive care.

Profile LinkedIn 

Dr. Paolo Bossi is a medical oncologist devoted to head and neck cancer treatment. He is particularly dedicated to rare head and neck cancers (paranasal sinus cancer, adnexal cancer, nasopharyngeal cancer, salivary gland cancer). He is currently evaluating the impact of treatment and treatment-induced toxicities in elderly patients. He is greatly committed to supportive care and is studying the impact of the microbioma in the development of treatment-related toxicities. He is also dedicated to non-melanoma skin cancer, with a strong commitment to translational evaluation of the response to new drugs.